DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Robert C, Ribas A, Hamid O. et al.
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
J Clin Oncol 2016;
34: 9503-9503
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.